

ESPERION THERAPEUTICS INC/MI
Form SC 14D9/A
January 08, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14D-9
(RULE 14d-101)

SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d) (4)
OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)

ESPERION THERAPEUTICS, INC.
(Name of Subject Company)

ESPERION THERAPEUTICS, INC.
(Name of Person(s) Filing Statement)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)

29664R 10 6
(CUSIP Number of Class of Securities)

ROGER S. NEWTON, PH.D.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
ESPERION THERAPEUTICS, INC.
3621 SOUTH STATE STREET
695 KMS PLACE
ANN ARBOR, MI 48108
(734) 332-0506

(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications on Behalf of the Person(s) Filing Statement)

With a copy to:
LINDA L. GRIGGS, ESQ.
MORGAN, LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE, NW
WASHINGTON, DC 20004
TELEPHONE: (202) 739-5245
FACSIMILE: (202) 739-3001

[] Check the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.

Esperion Therapeutics, Inc. ("the Company") hereby amends and
supplements its Solicitation/ Recommendation Statement on Schedule 14D-9 filed
with the Securities and Exchange Commission on January 7, 2004.

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form SC 14D9/A

ITEM 4. THE SOLICITATION OR RECOMMENDATION.

On January 8, 2004, the Company issued a press release announcing that the Duras Life Sciences Master Fund agreed to pay the Company \$32.2 million in settlement of a lawsuit filed by the Company. The press release is filed as Exhibit (a)(8) to this Amendment No. 1 to the Schedule 14D-9 and is incorporated herein by reference.

ITEM 9. EXHIBITS.

EXHIBIT

NO.	DESCRIPTION
(a)(8)	Press release, dated January 8, 2004, by Esperion Therapeutics, Inc., regarding the settlement with Duras Life Sciences Master Fund, Ltd.

-2-

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

By: /s/ Roger S. Newton, Ph.D.

Name: Roger S. Newton, Ph.D.

Title: President and Chief Executive Officer

Dated: January 8, 2004

-3-

EXHIBIT INDEX

EXHIBIT

NO.	DESCRIPTION
(a)(8)	Press release, dated January 8, 2004, by Esperion Therapeutics, Inc., regarding the settlement with Duras Life Sciences Master Fund, Ltd.

-3-